Recent Investment Analysts’ Ratings Changes for Ocugen (OCGN)

Several analysts have recently updated their ratings and price targets for Ocugen (NASDAQ: OCGN):

• 3/25/2026 – Ocugen had its “buy” rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
• 3/25/2026 – Ocugen had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a “buy” rating on the stock.
• 3/21/2026 – Ocugen was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/17/2026 – Ocugen is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $12.00 price target on the stock.
• 3/11/2026 – Ocugen is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $10.00 price target on the stock.
• 3/7/2026 – Ocugen was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/5/2026 – Ocugen had its “buy” rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.